Document Detail

Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin.
MedLine Citation:
PMID:  2575407     Owner:  NLM     Status:  MEDLINE    
BDF female mice inoculated with MXT mammary adenocarcinoma were treated for 30 days with microcapsules of the luteinizing hormone-releasing hormone (LH-RH) agonist D-Trp-6-LH-RH (releasing 25 micrograms/day for 30 days), microcapsules of the somatostatin agonist RC-160 (liberating 25 micrograms/day for one month), or the combination of these peptides. Bilateral surgical ovariectomy was performed in one group which served as an additional control. Tumor volume was measured weekly during the treatment period of 30 days. When tumor volume changes in the treated groups were compared to the corresponding changes in controls, the combination of D-Trp-6-LH-RH and RC-160 was the most effective in inhibiting tumor growth and approached the effect of surgical ovariectomy. At the conclusion of the experiment, tumor weights were also measured. All peptide analogs inhibited tumor weight by 42 to 63%. In the D-Trp-6-LH-RH treated group, ovarian weights and uterine weights decreased by 48% and 52%, respectively, as compared to controls. Histologically, the regressive changes in tumors caused by the treatment with RC-160, D-Trp-6-LH-RH and their combination were characterized by the coexistence of apoptosis (programmed cell death) and coagulation necrosis. The transition of apoptosis into coagulation necrosis was a common finding. The term 'apoptotic index' is proposed for the ratio of tumorous glands containing apoptotic cells. The apoptotic index was higher in the treated groups than in the control.
B Szende; K Lapis; T W Redding; G Srkalovic; A V Schally
Related Documents :
3814727 - Standardized tumor rates for chronic bioassays.
18830097 - Functional computed tomographic quantification of angiogenesis in rabbit vx2 soft-tissu...
18703747 - Hematologic and metabolic effects of dietary supplementation with agaricus sylvaticus f...
7251327 - Urinary diversion and systemic chemotherapy in the treatment of experimental early neop...
498037 - Chromosome analysis of primary large bowel tumors: a new method for improving the yield...
6956767 - Electron microscopic autoradiography of the trachea in fetal syrian golden hamsters tre...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  14     ISSN:  0167-6806     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  1989 Dec 
Date Detail:
Created Date:  1990-03-12     Completed Date:  1990-03-12     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  307-14     Citation Subset:  IM    
Endocrine, Polypeptide and Cancer Institute, Veterans Administration Medical Center, New Orleans, LA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / drug therapy*,  pathology
Cell Survival / drug effects*
Gonadotropin-Releasing Hormone / analogs & derivatives*,  therapeutic use
Luteinizing Hormone / blood
Mammary Neoplasms, Experimental / drug therapy*,  pathology
Mice, Inbred Strains
Organ Size / drug effects
Ovary / drug effects
Radioligand Assay
Somatostatin / analogs & derivatives*,  therapeutic use
Uterus / drug effects
Grant Support
Reg. No./Substance:
33515-09-2/Gonadotropin-Releasing Hormone; 51110-01-1/Somatostatin; 9002-67-9/Luteinizing Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced b...
Next Document:  Immunomodulators and feeding regulation: a humoral link between the immune and nervous systems.